Find clinical trials

This research study is looking at whether the oral supplement TRU NIAGEN®, a form of Vitamin B, can increase the levels of the molecule NAD+ in the blood and heart muscle. NAD+ is essential for energy production in the human body. Research has shown decreased NAD+ levels in the heart muscle of patients with a condition of heart failure known as heart failure with preserved ejection fraction (HFpEF) or stiff heart failure. TRU NIAGEN® has been shown to increase the level of NAD+ in the blood, however whether it can increase NAD+ in the heart muscle is unknown. Replenishing NAD+ in the heart could be beneficial to HFpEF patients and/ or patients whose hearts don’t relax properly. The aim of the study is to see whether taking the oral supplement TRU NIAGEN® for three months can improve your heart function, exercise tolerance, glucose tolerance, and blood pressure.

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.